Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Hidetoshi Eguchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2318-1129; OpenAlex author ID A5073472318. Sources: OpenAlex.

Their work

Papers
128 (first author 16, last author 31)
Trials
0
Grants
0
Labs led
1
Collaborators
239
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 8 papers · 2014: 5 papers · 2015: 9 papers · 2016: 6 papers · 2017: 11 papers · 2018: 10 papers · 2019: 6 papers · 2020: 8 papers · 2021: 6 papers · 2022: 9 papers · 2023: 13 papers · 2024: 18 papers · 2025: 6 papers · 2026: 9 papers

Papers 50 of 128

  1. Relationship Between Radiographic and Pathological Portal Vein-Superior Mesenteric Vein Involvement in Neoadjuvant Treatment for Pancreatic Cancer: A Comparati… Last author DOI 10.1002/wjs.70395↗
  2. Shrinkage paradox in intraductal papillary mucinous neoplasms is associated with higher concomitant pancreatic cancer risk. Co-author DOI 10.1007/s00330-026-12740-z↗
  3. A soft tissue mass around the arteries after pancreatectomy: the association with local recurrence and the impact of neoadjuvant radiotherapy in pancreatic duc… Last author DOI 10.1007/s00595-026-03341-w↗
  4. Is neoadjuvant therapy necessary for resectable pancreatic cancer? A review of randomized controlled trials to date: a narrative review. Co-author DOI 10.1007/s10147-025-02923-x↗
  5. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  6. Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). Last author DOI 10.1371/journal.pone.0345459↗
  7. Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment respo… Last author DOI 10.3892/ijo.2026.5849↗
  8. Enterococcus faecalis is involved in the progression of the early stages of latent chronic pancreatitis surrounding pancreatic cancer tissue Co-author DOI 10.64898/2026.07.20.739687↗
  9. Prohaptoglobin Promotes Pancreatic Cancer Progression by sustaining YAP Activity Co-author DOI 10.64898/2026.07.26.740853↗
  10. Discrepancy Between Radiographic and Pathological Response Assessment in Neoadjuvant Treatment for Pancreatic Cancer: A Comparison Between Neoadjuvant Chemothe… Last author DOI 10.1002/ags3.70047↗
  11. Dynamic contrast-enhanced CT-derived extracellular volume fraction for predicting postoperative oncologic outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejrad.2025.112246↗
  12. Response to the letter to the editor: "Refining the prognostic utility of CA19-9 in neoadjuvant therapy for pancreatic cancer: Emphasizing serial monitoring an… Last author DOI 10.1016/j.pan.2025.09.033↗
  13. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  14. The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization. Last author DOI 10.1186/s12876-025-04108-2↗
  15. ASO Author Reflections: Efficacy of SOAT1 Inhibitors against Pancreatic Cancer with TP53 Mutations. Last author DOI 10.1245/s10434-025-17667-1↗
  16. Removal of gemcitabine-induced senescent cancer cells by targeting glutaminase1 improves the therapeutic effect in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ijc.34725↗
  17. Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study. Last author DOI 10.1002/jso.27792↗
  18. Diagnostic impact of postoperative CA19-9 dynamics on pancreatic cancer recurrence: a single-institution retrospective study. Last author DOI 10.1007/s13304-024-01758-x↗
  19. Pancreatic fibrosis assessment and association with pancreatic cancer: comparison with the extracellular volume fraction. Co-author DOI 10.1016/j.crad.2024.08.007↗
  20. Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plus pancreatic ductal adenocarcinoma patie… Last author DOI 10.1016/j.ejso.2024.108650↗
  21. Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: Optimization using machine learning and network anal… Last author DOI 10.1016/j.pan.2024.09.009↗
  22. Organ-specific variations in tumor marker dynamics in postoperative pancreatic cancer recurrence: Trends in lung and liver recurrence highlighting biological h… Last author DOI 10.1016/j.suronc.2024.102103↗
  23. Clinical impact of high-quality testing for peritoneal lavage cytology in pancreatic cancer. Last author DOI 10.1038/s41598-024-60936-4↗
  24. High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. Co-author DOI 10.1111/cas.16152↗
  25. ASO Author Reflections: A Novel Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers Enhances Predictive Significance in Patients with a Modest Radi… Last author DOI 10.1245/s10434-024-15021-5↗
  26. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-024-15118-x↗
  27. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline… Last author DOI 10.1245/s10434-024-15199-8↗
  28. ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pa… Last author DOI 10.1245/s10434-024-15244-6↗
  29. ASO Author Reflections: A Novel Mechanism of Anticancer Effect of Skeletal Muscle-Derived Irisin in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-024-15349-y↗
  30. MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pone.0310328↗
  31. Lymphocyte Antigen 6 Family Member D (LY6D) Affects Stem Cell Phenotype and Progression of Pancreatic Adenocarcinoma. Co-author DOI 10.21873/anticanres.17300↗
  32. Circulating tumor-associated antigen-specific IFNγ+4-1BB+ CD8+ T cells as peripheral biomarkers of treatment outcomes in patients with pancreatic cancer. Co-author DOI 10.3389/fimmu.2024.1363568↗
  33. Significance of signal recognition particle 9 nuclear translocation: Implications for pancreatic cancer prognosis and functionality. Co-author DOI 10.3892/ijo.2024.5662↗
  34. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  35. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… First author DOI 10.1002/cncr.34580↗
  36. Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00280-023-04531-w↗
  37. Pancreatic cancer near the splenic hilum has a higher likelihood of splenic vessel invasion and unfavorable survival. Last author DOI 10.1007/s00423-023-03089-8↗
  38. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… First author DOI 10.1007/s00535-023-01988-7↗
  39. Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy. Last author DOI 10.1007/s10147-023-02306-0↗
  40. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  41. Pathological Nodal and Vascular Involvement Significantly Impacts the Recurrence Risk in Different Time Frames in Patients With Resectable and Borderline Resec… Co-author DOI 10.1097/sla.0000000000005879↗
  42. Multifaced roles of desmoplastic reaction and fibrosis in pancreatic cancer progression: Current understanding and future directions. Co-author DOI 10.1111/cas.15890↗
  43. Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity. Co-author DOI 10.1186/s13046-023-02831-w↗
  44. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma U… Last author DOI 10.1245/s10434-022-12985-0↗
  45. ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancre… Last author DOI 10.1245/s10434-022-13024-8↗
  46. The impact of cellular senescence and senescence‑associated secretory phenotype in cancer‑associated fibroblasts on the malignancy of pancreatic cancer. Last author DOI 10.3892/or.2023.8535↗
  47. Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cnr2.1582↗
  48. Pancreatic fibrosis by extracellular volume fraction using Contrast-enhanced computed tomography and relationship with pancreatic cancer. Co-author DOI 10.1016/j.ejrad.2022.110522↗
  49. Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. Co-author DOI 10.1016/j.isci.2022.104659↗
  50. N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-022-15196-5↗

Closest collaborators

The 25 strongest of 239 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichiro Doki · 92 shared papers, 2011–2026 · strength 10.20
  2. Daisaku Yamada · 58 shared papers, 2015–2026 · strength 8.29
  3. Yoshito Tomimaru · 48 shared papers, 2013–2026 · strength 6.47
  4. Hirofumi Akita · 41 shared papers, 2011–2026 · strength 5.80
  5. Yoshifumi Iwagami · 43 shared papers, 2013–2026 · strength 5.80
  6. Tadafumi Asaoka · 46 shared papers, 2014–2026 · strength 5.52
  7. Hidenori Takahashi · 32 shared papers, 2011–2026 · strength 5.31
  8. Kazuki Sasaki · 23 shared papers, 2022–2025 · strength 3.86
  9. Masahiro Tanemura · 32 shared papers, 2011–2026 · strength 3.19
  10. Kunihito Gotoh · 28 shared papers, 2012–2024 · strength 2.64
  11. Hideshi Ishii · 18 shared papers, 2014–2024 · strength 1.79
  12. Yutaka Takeda · 19 shared papers, 2011–2024 · strength 1.56
  13. Hiroaki Nagano · 32 shared papers, 2011–2021 · strength 1.47
  14. Shinichiro Hasegawa · 11 shared papers, 2014–2026 · strength 1.46
  15. Eiji Miyoshi · 10 shared papers, 2013–2026 · strength 1.04
  16. Noriyuki Tomiyama · 7 shared papers, 2015–2026 · strength 0.98
  17. Yasunari Fukuda · 6 shared papers, 2017–2026 · strength 0.93
  18. Sohei Satoi · 10 shared papers, 2013–2025 · strength 0.92
  19. Satoru Miyahara · 4 shared papers, 2024–2025 · strength 0.89
  20. Yu Takeda · 6 shared papers, 2020–2024 · strength 0.88
  21. Hideyuki Fukui · 5 shared papers, 2019–2026 · strength 0.87
  22. Michiaki Unno · 7 shared papers, 2016–2026 · strength 0.80
  23. Hiroki Yamaue · 9 shared papers, 2013–2025 · strength 0.78
  24. Tomoaki Hara · 5 shared papers, 2022–2024 · strength 0.77
  25. Hiromichi Sato · 5 shared papers, 2022–2024 · strength 0.77

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.